Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01747538




Registration number
NCT01747538
Ethics application status
Date submitted
7/12/2012
Date registered
11/12/2012
Date last updated
12/07/2016

Titles & IDs
Public title
Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment
Scientific title
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects With Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled With Systemic Treatment
Secondary ID [1] 0 0
2012-001609-25
Secondary ID [2] 0 0
X052131/CL3-78989-006
Universal Trial Number (UTN)
Trial acronym
EYEGUARD™-C
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Uveitis 0 0
Condition category
Condition code
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Dose 1 gevokizumab
Treatment: Drugs - Dose 2 gevokizumab

Placebo Comparator: Placebo -

Experimental: Dose 1 gevokizumab -

Experimental: Dose 2 gevokizumab -


Treatment: Drugs: Placebo
Solution for subcutaneous injection

Treatment: Drugs: Dose 1 gevokizumab
Solution for subcutaneous injection

Treatment: Drugs: Dose 2 gevokizumab
Solution for subcutaneous injection
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of subjects with an occurrence of uveitic disease through Day 168
Timepoint [1] 0 0
Day 0 through Day 168
Secondary outcome [1] 0 0
Time to first occurrence of uveitic disease
Timepoint [1] 0 0
Day 0 through Day 168

Eligibility
Key inclusion criteria
- Diagnosis of non-infectious intermediate, posterior, or pan- uveitis in at least one
eye

- Controlled uveitic disease in both eyes

- Stable dose of oral corticosteroids in combination with selected stable
immunosuppressive therapy

- Effective contraceptive measures
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Infectious uveitis and masquerade syndromes

- Isolated anterior uveitis

- Contraindication to mydriatics

- Active tuberculosis disease

- History of allergic or anaphylactic reactions to monoclonal antibodies

- History of recurrent infection or predisposition to infection; active ocular infection

- Pregnant or nursing women

Other protocol-defined inclusion/exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
281
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Recruitment hospital [1] 0 0
- Sydney
Recruitment hospital [2] 0 0
- East Melbourne
Recruitment hospital [3] 0 0
- Nedlands
Recruitment hospital [4] 0 0
- Darlinghurst, New South Wales
Recruitment postcode(s) [1] 0 0
- Sydney
Recruitment postcode(s) [2] 0 0
- East Melbourne
Recruitment postcode(s) [3] 0 0
- Nedlands
Recruitment postcode(s) [4] 0 0
- Darlinghurst, New South Wales
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Iowa
Country [11] 0 0
United States of America
State/province [11] 0 0
Maine
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Minnesota
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
Nebraska
Country [18] 0 0
United States of America
State/province [18] 0 0
New Jersey
Country [19] 0 0
United States of America
State/province [19] 0 0
North Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
North Dakota
Country [21] 0 0
United States of America
State/province [21] 0 0
Ohio
Country [22] 0 0
United States of America
State/province [22] 0 0
Oregon
Country [23] 0 0
United States of America
State/province [23] 0 0
Pennsylvania
Country [24] 0 0
United States of America
State/province [24] 0 0
Tennessee
Country [25] 0 0
United States of America
State/province [25] 0 0
Texas
Country [26] 0 0
United States of America
State/province [26] 0 0
Utah
Country [27] 0 0
United States of America
State/province [27] 0 0
Virginia
Country [28] 0 0
Argentina
State/province [28] 0 0
Buenos Aires
Country [29] 0 0
Argentina
State/province [29] 0 0
Santa Fe
Country [30] 0 0
Armenia
State/province [30] 0 0
Yerevan
Country [31] 0 0
Brazil
State/province [31] 0 0
MG
Country [32] 0 0
Brazil
State/province [32] 0 0
Rio de Janeiro
Country [33] 0 0
Brazil
State/province [33] 0 0
San Paulo
Country [34] 0 0
Canada
State/province [34] 0 0
Ontario
Country [35] 0 0
Canada
State/province [35] 0 0
Quebec
Country [36] 0 0
China
State/province [36] 0 0
Beijing
Country [37] 0 0
China
State/province [37] 0 0
Chongqing
Country [38] 0 0
China
State/province [38] 0 0
Hong Kong
Country [39] 0 0
France
State/province [39] 0 0
Lyon
Country [40] 0 0
France
State/province [40] 0 0
Nantes
Country [41] 0 0
France
State/province [41] 0 0
Paris
Country [42] 0 0
Germany
State/province [42] 0 0
Berlin
Country [43] 0 0
Germany
State/province [43] 0 0
Chemnitz
Country [44] 0 0
Germany
State/province [44] 0 0
Heidelberg
Country [45] 0 0
Germany
State/province [45] 0 0
Muenster
Country [46] 0 0
Germany
State/province [46] 0 0
Tüebingen
Country [47] 0 0
Greece
State/province [47] 0 0
Mezourlo, Larissa
Country [48] 0 0
Israel
State/province [48] 0 0
Jerusalem
Country [49] 0 0
Israel
State/province [49] 0 0
Petoch Tikvah
Country [50] 0 0
Israel
State/province [50] 0 0
Tel Aviv
Country [51] 0 0
Italy
State/province [51] 0 0
Ancona, Marche
Country [52] 0 0
Italy
State/province [52] 0 0
Genova
Country [53] 0 0
Italy
State/province [53] 0 0
Milano
Country [54] 0 0
Italy
State/province [54] 0 0
Padova
Country [55] 0 0
Italy
State/province [55] 0 0
Padua
Country [56] 0 0
Italy
State/province [56] 0 0
Romagna
Country [57] 0 0
Mexico
State/province [57] 0 0
Distrito Federal
Country [58] 0 0
Mexico
State/province [58] 0 0
Mexico City
Country [59] 0 0
Mexico
State/province [59] 0 0
Nuevo Leon
Country [60] 0 0
Mexico
State/province [60] 0 0
Tijuana
Country [61] 0 0
Poland
State/province [61] 0 0
Gdansk
Country [62] 0 0
Poland
State/province [62] 0 0
Katowice
Country [63] 0 0
Poland
State/province [63] 0 0
Lublin
Country [64] 0 0
Poland
State/province [64] 0 0
Warszawa
Country [65] 0 0
Portugal
State/province [65] 0 0
Braga
Country [66] 0 0
Portugal
State/province [66] 0 0
Coimbra
Country [67] 0 0
Portugal
State/province [67] 0 0
Lisboa
Country [68] 0 0
Russian Federation
State/province [68] 0 0
Khabarovsk
Country [69] 0 0
Russian Federation
State/province [69] 0 0
Novosibirsk
Country [70] 0 0
Russian Federation
State/province [70] 0 0
Saint-Petersburg
Country [71] 0 0
South Africa
State/province [71] 0 0
Durban
Country [72] 0 0
South Africa
State/province [72] 0 0
Johannesburg, Gauteng
Country [73] 0 0
Spain
State/province [73] 0 0
Barcelona
Country [74] 0 0
Spain
State/province [74] 0 0
Granada
Country [75] 0 0
Spain
State/province [75] 0 0
Madrid
Country [76] 0 0
Spain
State/province [76] 0 0
Malaga
Country [77] 0 0
Taiwan
State/province [77] 0 0
Taoyuan
Country [78] 0 0
Taiwan
State/province [78] 0 0
Taïpeï City
Country [79] 0 0
Tunisia
State/province [79] 0 0
Monastir
Country [80] 0 0
Turkey
State/province [80] 0 0
Ankara
Country [81] 0 0
Turkey
State/province [81] 0 0
Cerrahpasa, Istanbul
Country [82] 0 0
Turkey
State/province [82] 0 0
Faith, Istanbul
Country [83] 0 0
United Kingdom
State/province [83] 0 0
Tyne and Wear
Country [84] 0 0
United Kingdom
State/province [84] 0 0
Bristol
Country [85] 0 0
United Kingdom
State/province [85] 0 0
Liverpool
Country [86] 0 0
United Kingdom
State/province [86] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
XOMA (US) LLC
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Institut de Recherches Internationales Servier
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the efficacy of gevokizumab in reducing the risk of
recurrent uveitic disease in subjects with non-infectious uveitis whose disease is currently
controlled with systemic treatment.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01747538
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01747538